ArticleAlzheimer's & dementia (New York, N. Y.)

The HOPE4MCI study: A randomized double-blind assessment of AGB101 for the treatment of MCI due to AD.

Richard Mohs et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.